AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
CHARM shows ATACAND reduces risk of cardiovascular death.
2003 OCT 2 - (NewsRx.com & NewsRx.net) -- In a comprehensive trial program with an angiotensin receptor blocker (ARB) for heart failure, AstraZeneca's ATACAND (candesartan cilexetil) has been shown to improve survival in patients with chronic symptomatic heart failure (CHF) and diminished left ventricle (LV) function.
The overall program results demonstrate that ATACAND (n=1150) reduces cardiovascular (CV) deaths or hospital admissions for heart failure by 16% when compared to placebo, across a broad spectrum of patients with symptomatic heart failure, irrespective of other concomitant heart failure therapies, ejection fraction, age, or gender. ATACAND is approved for the treatment of hypertension; it is not currently indicated for heart failure.
Findings from the clinical program known as CHARM (candesartan in heart failure assessment of reduction in mortality and morbidity) were presented at the annual meeting of the European Society of Cardiology Congress, and published in the September 6 edition of The Lancet.
...- Landmark Study Shows ATACAND(R) Reduces Risk of Cardiovascular Death In...
- Press release article from: PR Newswire September 2, 2003 700+ words
...ARB) for heart failure, AstraZeneca's ATACAND(R) (candesartan...demonstrate that ATACAND (n=1150...admissions for heart failure by 16% when...concomitant heart failure therapies...or gender. ATACAND is approved...
- Landmark Study Shows ATACAND(R) Reduces Risk of Cardiovascular Death in...
- Press release article from: PR Newswire August 31, 2003 700+ words
...ARB) for heart failure, AstraZeneca's ATACAND(R) (candesartan...demonstrate that ATACAND (n=1150...admissions for heart failure by 16% when...concomitant heart failure therapies...or gender. ATACAND is approved...
- Combined Use of ATACAND(R) (candesartan cilexetil) and ACE Inhibitor Improves...
- Press release article from: PR Newswire May 4, 2006 700+ words
...the benefits of adding ATACAND to heart failure treatment regimens irrespective...updated indication for heart failure. ATACAND is indicated for the...cardiovascular death and to reduce heart failure hospitalizations. ATACAND also has an added effect...
- AstraZeneca Submits sNDA for ATACAND(R) to Treat Patients with Chronic Heart...
- Press release article from: PR Newswire July 1, 2004 700+ words
...treatment of chronic heart failure (CHF). ATACAND is currently...the effects of ATACAND on cardiovascular...admissions for heart failure when compared...http://www.atacand-us.com/. About Chronic Heart Failure Chronic heart...
- CHARM Programme demonstrates clear benefits of Atacand in the treatment of...
- Press release article from: PR Newswire August 31, 2003 700+ words
...with chronic heart failure. Importantly, Atacand is the first...for chronic heart failure including an ACE inhibitor, Atacand demonstrated...for chronic heart failure showed a trend...in favour of Atacand (p=0.118...
- New Data Showed Results of AstraZeneca's ATACAND in Broad Spectrum of Patients...
- Press release article from: PR Newswire March 9, 2004 700+ words
...Candesartan in Heart failure Assessment of Reduction...already showed ATACAND reduces cardiovascular...admissions for heart failure by 16% when compared...other concomitant heart failure therapies, ejection...age or gender. ATACAND is approved for...
- CHARM: new analysis shows Atacand benefit.(Candesartan in Heart Failure -...
- Newspaper article from: Pharma Marketletter June 13, 2005 700+ words
...European Journal of Heart Failure, reveals that...receptor blocker Atacand (candesartan cilexetil...improvement in their heart failure symptoms compared...already demonstrated Atacand to be the first...both death and heart failure hospital admissions...
- AstraZeneca says Atacand is cost effective in treating heart failure.(Brief...
- Newspaper article from: Pharma Marketletter June 19, 2006 700+ words
AstraZeneca says that the direct cost of adding its hypertension drug Atacand (candesartan cilexetil) to standard heart failure therapy is compensated by a significant reduction in hospital admissions, according to an...